Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.026
Sell
RSI(14)
42.998
Neutral
STOCH(KDJ)(9,3,3)
23.457
Buy
ATR(14)
0.168
Low Volatility
CCI(14)
-124.392
Sell
Williams %R
62.852
Sell
TRIX(12,20)
-0.539
Sell
StochRSI(14)
100.000
Buy
Search
BioLine RX Ltd
BLRXAdd to Watchlist
2.820USD
+0.100+3.72%
Close 07-31 16:00（ET）Quotes delayed by 15 min
12.27MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+3.72%
5 Days
0.00%
1 Month
-9.62%
6 Months
-9.32%
Year to Date
+1.81%
1 Year
-29.15%
Key Figures
2.730Open
2.820High
9.65KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.22%Turnover Ratio
2.700Prev. Close
2.649Low
22.31KTurnover
LossP/E Static
0.63P/B
0.00%Div Yield TTM
-5.08%ROA
7.77052wk High
1.32Volume Ratio
-9.22MNet Profit
4.35MShares
-0.4920EPS TTM
1.49Beta
-12.80%ROE
2.15052wk Low
6.35%Amplitude
79.38%Gross Margin
12.27MMarket Cap
-4.83Reward/Risk
3.69%Risk Rate
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2026-07-31Key Insights
BioLine RX Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 119 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.18M.
Overvalued
The company’s latest PE is -5.73, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.33K shares, decreasing 69.29% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
17.500
Target Price
+536.36%
Upside Space
BioLine RX Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
17.500
Target Price
+536.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
1
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.779
Buy
MA10
2.818
Buy
MA20
2.928
Sell
MA50
3.115
Sell
MA100
2.851
Sell
MA200
3.001
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioLine RX Ltd Info
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Ticker SymbolBLRX
CompanyBioLine RX Ltd
CEOSerlin (Philip Adam)
Websitehttps://www.biolinerx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of BioLine RX Ltd (BLRX)?
The current price of BioLine RX Ltd (BLRX) is 2.82.
What is the symbol of BioLine RX Ltd?
The ticker symbol of BioLine RX Ltd is BLRX.
What is the 52-week high of BioLine RX Ltd?
The 52-week high of BioLine RX Ltd is 7.77.
What is the 52-week low of BioLine RX Ltd?
The 52-week low of BioLine RX Ltd is 2.15.
What is the market capitalization of BioLine RX Ltd?
The market capitalization of BioLine RX Ltd is 12.27M.
Is BioLine RX Ltd (BLRX) currently rated as Buy, Hold, or Sell?
According to analysts, BioLine RX Ltd (BLRX) has an overall rating of Buy, with a price target of 17.50.
What is the Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX)?
The Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX) is -0.49.